• Arizona is one of the most attractive mining jurisdictions in the world and hands down the biggest producer of copper in the U.S.
• Arizona Metals’ flagship project, Kay Mine, is surrounded by 60 past producing underground VMS copper-gold-zinc-silver mines
• 72,000 meters have been drilled to date in Phases 1 and 2 at Kay Mine, to prove historic resource estimates and with CDN$60 million in the bank, Arizona Metals is ready to complete Phase 2 and initiate Phase 3 drilling now that Bureau of Land Management (“BLM”) has approved drill pads

Arizona is the United States’ largest producer of copper without question, as the state was responsible for 71% of the country’s copper production in 2021. Looking ahead, there are clear signs that Arizona will continue to dominate a market expected to see increasing demand owing to the rise of electric vehicles. In its bid to add its name to Arizona’s rich mining history, Arizona Metals (TSX: AMC) (OTCQX: AZMCF) hit a big milestone at the end of October that paves the way for resources and reserves at its expansive project north of Phoenix. Laden with copper, gold and other metals, Arizona is ranked 2nd out of 77 jurisdictions for investment attractiveness by the venerable Fraser Institute. It is not without reason that the state is a host to mines and projects owned by some of the most recognizable names in the mining business, such as Rio Tinto, Freeport, and Hudbay. Arizona Metals has two projects, Kay Mine and Sugarloaf Peak, in prolific mining districts, both of which have substantial historic resources that the company is aiming to bring current and expand upon. Kay Mine is the flagship project in Yavapai County, covering 1,300 acres on a combination of patented and Bureau of Land Management (“BLM”) claims. The project is 100% owned by Arizona Metals, not subject to any royalties, and is surrounded by 60 past producing underground VMS (Volcanogenic Massive Sulphide) copper-gold-zinc-silver mines. VMS deposits are known to be rich in metals and often found in clusters. Glencore’s Kidd Mine just north of Timmins, Ontario, Canada is the posterchild for the potential of VMS deposits. It has been producing for 56 years and has turned out over 9 million tonnes of zinc (“Zn”), 3.4 million tonnes of copper (“Cu”), and 12,000 tonnes of silver (“Ag”). It is the deepest base metal mine in the world, with mining activities ongoing at 9,600 feet (nearing 2 miles) below surface. Arizona Metals’ Kay Mine Deposit is unique in that it is a gold-rich VMS deposit; there are very few of these left in the world that are not currently in production or owned by major producers. About an hour to the north of Kay Mine, Phelps Dodge’s United Verde Mine produced 30 million tonnes at 5% Cu from an open pit and 4 million tonnes at 10% Cu from underground mining. About an hour to the southeast of Kay, is Rio Tinto’s vaunted Resolution Mine that is estimated to produce up to 40 billion pounds of copper over 40 years when it comes online. Kay Mine has an historic resource estimate* of 5.8 million tonnes at 2.8 grams per tonne (g/t) gold (“Au”), 2.2% Cu, 3.03% Zn, and 55 g/t Ag, according to work completed by Exxon Minerals in 1982. In a Phase 1 drill program, Arizona Metals spent CDN$25 million drilling 72,000 meters across 2-1/2 years to better understand the Kay Mine deposit. The drilling returned a spate of positive data, including intercepts of 43.1m grading 3.94% CuEq (copper equivalent), including 15.2m of 6.7% CuEq, from a depth of 341m and 38.4m grading 2.9% CuEq, incl. 12.5m of 6.0% CuEq, from a depth of 385m. The Au-Zn Discovery Zone hit 93.3m grading 8.3 g/t AuEq (gold equivalent), including a sub-interval of 17.5m grading 29.6 g/t AuEq. About 200m below this, drilling intersected another copper-rich zone of 125.3 m at 3.2% CuEq. Grades and widths of this magnitude have typically only been encountered historically in world-class deposits and mines. All equivalent calculations are after assumed mining recoveries. The exploration work has shown Kay Mine to be a steeply dipping VMS deposit defined from a depth of 60 meters to at least 900 meters. Mineralization remains open for expansion on strike and at depth. Particularly compelling is the fact that drilling to date has only explored about 3% of the prospective mineral horizon. That is about to change, as Arizona Metals has now received permit approval from the Arizona BLM for two new drill pads, located approximately 1,200 meters west of the Kay Mine deposit. Arizona Metals is fully funded with approximately CDN$60 million in cash at the end of the first half of the year as it continues its Phase 2 and initiates its Phase 3 drill programs that will continue to test high priority targets at Kay, as well as the 97% of the untested horizon. The company has earmarked CDN$27 million to drill 18,000 meters in the Phase 2 programs, followed by ~76,000 meters in a Phase 3 drilling program focusing on its Central and Western targets in the search for new discoveries within the vicinity of the known deposit. Construction of the drill road for the Central target (located 500 meters west of the Kay Mine deposit) is complete. Road construction for the Western target will begin upon confirmation of BLM acceptance of the company’s posted bond by year end with drilling to commence in Q1 2023. Since the company was listed in 2019, equity research analysts at the Bank of Montreal, Scotiabank, National Bank, Stifel, Clarus Securities, Beacon Securities and Agentis Capital have published reports on Arizona Metals with 12-month target prices ranging from CDN$$6.50 to $10.50 per share. * The historic estimate at the Kay Mine was reported by Exxon Minerals in 1982. The historic estimate has not been verified as a current mineral resource. None of the key assumptions, parameters, and methods used to prepare the historic estimate were reported, and no resource categories were used. Significant data compilation, re- drilling and data verification may be required by a “qualified person” (as defined in National Instrument 43-101 – Standards of Disclosure for Mineral Projects) before the historic estimate can be verified and upgraded to be a current mineral resource. A qualified person has not done sufficient work to classify it as a current mineral resource, and Arizona Metals is not treating the historic estimate as a current mineral resource. Full Disclosure: Arizona Metals Corp. is an Investor Brand Network marketing client. For more information, visit the company’s website at www.ArizonaMetalsCorp.com. NOTE TO INVESTORS: The latest news and updates relating to AZMCF are available in the company’s newsroom at https://ibn.fm/AZMCF

• New Chief Medical Officer will play a major role in defining best paths to adoption, clinical strategies, and partnerships
• Dr. Fitzgerald serves as director of the Center for Cardiovascular Technology and of the Cardiovascular Core Analysis Laboratory at Stanford University Medical School
• Dr. Fitzgerald brings impressive expertise in the clinical, research and industry sectors

In a display of its commitment to offering innovative, high-quality products and services, cardiac tech company HeartBeam (NASDAQ: BEAT) has named a world-renowned interventional cardiologist with an impressive breadth of experience as its Chief Medical Officer (https://ibn.fm/pN1kf). Stanford cardiologist Peter J. Fitzgerald, MD, PhD, will help HeartBeam continue to develop the first and only 3D-vector ECG platform for heart attack detection anytime, anywhere. “We are thrilled to have Dr. Fitzgerald, one of the world’s preeminent opinion leaders in cardiology and digital health, join the HeartBeam leadership team and play a major role in defining best paths to adoption, clinical strategies, and partnerships to advance our products in the market,” said HeartBeam founder and CEO Branislav Vajdic, PhD. “In addition to his cardiovascular clinical and research expertise, Dr. Fitzgerald has a rich history of developing successful collaborations with partners in the industry and has developed deep connections across the investment and medical communities.” Dr. Fitzgerald joins HeartBeam after gaining invaluable experience in the clinical, research and industry sectors. An accomplished inventor, entrepreneur, and investment-fund founder, Dr. Fitzgerald is serving as director of the Center for Cardiovascular Technology and director of the Cardiovascular Core Analysis Laboratory at Stanford University Medical School. He is a professor emeritus from the Department of Medicine (Cardiology) at Stanford University and has been integrally involved in more than 175 clinical trials. His expertise as an author is profound, with more than 650 manuscripts or chapters to his name. He is also a prominent speaker and trainer, having lectured around the world and trained more than 150 post-doctoral candidates in engineering and medicine. Outside of the academic world, Dr. Fitzgerald has been principal and founder of 24 medical-device companies, leading 18 of those from start-up stage to becoming medium-cap or large-cap life-science companies. In addition, he cofounded Israeli-based TriVentures, an incubator/venture fund targeting early-stage medical technology and digital health. Finally, for the past two decades, Dr. Fitzgerald has served as a consultant to the U.S. Food and Drug Administration (“FDA”), where his focus has been on medical technology and data-driven health analytics. With his PhD in electrical engineering and extensive background, Dr. Fitzgerald is imminently qualified for his new position. “HeartBeam’s focus on bringing novel diagnostic tools to cardiac patients, especially those with a high risk for a heart attack, could have a significant, positive impact on medical outcomes and quality of life for patients while potentially saving healthcare dollars,” said Dr. Fitzgerald. “I look forward to supporting the planned advancement of the Company’s rich product pipeline to deliver comprehensive cardiac care for patients anytime, anywhere.” HeartBeam is a cardiac technology company that has developed the first and only 3D-vector ECG platform for heart attack detection anytime, anywhere. By applying a suite of proprietary algorithms to simplify vector electrocardiography (“VECG”), the HeartBeam platform enables patients and their clinicians to quickly and easily determine if symptoms are due to a heart attack so care can be expedited, if required. HeartBeam has two patented products in development: HeartBeam AIMI(TM) is software for acute-care settings that provides a 3D comparison of baseline and symptomatic 12-lead ECG to identify a heart attack more accurately. HeartBeam AIMIGo(TM) is the first and only credit-card-sized 12-lead output ECG device coupled with a smartphone app and cloud-based diagnostic software system to facilitate remote heart attack detection. HeartBeam AIMI and AIMIGo have not yet been cleared by the FDA for marketing in the USA or other geographies. For more information, visit the company’s website at www.HeartBeam.com. NOTE TO INVESTORS: The latest news and updates relating to BEAT are available in the company’s newsroom at https://ibn.fm/BEAT

• Lexaria Bioscience has launched DEM-A22-1, its first-ever study to investigate whether its patented DehydraTECH(TM)-processed CBD may have therapeutic use against dementia
• The animal study will involve a total of 32 Long Evans rats and will involve a memory assessment test that will be utilized to investigate whether CBD enables cognitive performance enhancements
• Previous independent studies have shown that CBD prevents the development of a social recognition deficit, a symptom frequently reported in Alzheimer’s disease patients, and is linked to memory impairment
• The laboratory work is expected to complete January 2023, with data and reporting to follow likely in April 2023

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, is working on implementing its commercial strategies around the highly patented DehydraTECH(TM) drug delivery technology, with these strategies firmly anchored in and driven by R&D studies. According to company CEO Chris Bunka’s letter to shareholders, the company’s plans for 2022 included the launch and completion of several major applied studies as well as many smaller programs (https://ibn.fm/3nKvC). In line with these plans, the company has so far launched – and announced the successful results of – its most comprehensive hypertension study yet, HYPER-H21-4 (https://ibn.fm/CucaJ), and has received an Independent Review Board (“IND”) approval to commence its planned human oral nicotine study (https://ibn.fm/HFvwF). At the same time, Lexaria has also set out to study the effect of DehydraTECH-processed cannabidiol (“CBD”) on diabetes and, more recently, announced it would commence its study program DEM-A22-1. A dose-ranging, two-month program involving 32 Long Evans rats dosed with DehydraTECH-CBD, DEM-A22-1 is Lexaria’s first-ever study to investigate whether DehydraTECH-CBD may potentially have therapeutic utility against dementia. It will be undertaken by a leading, third-party testing lab in Canada, with the laboratory work expected to complete in late January 2023 and results reported likely in April 2023. “The study is a novel object recognition test which is widely used to assess memory in rodents, and is being utilized to investigate whether CBD enables cognitive performance enhancements in this model, potentially of utility in dementia treatment,” the company’s November 10 press release explains (https://ibn.fm/U9vSy). CBD has been the subject of many studies evaluating the effects of the compound on neurogenerative diseases and dementia (https://ibn.fm/8s2sO). One such study, published in 2014 in the Journal of Alzheimer’s Disease, demonstrated CBD’s ability to prevent the development of a social recognition memory deficit in AD (Alzheimer’s disease) transgenic mice (https://ibn.fm/deJQr). Social or facial recognition memory reflects the ability of social animals – including mice – to recognize and remember familiar individuals of the same species (https://ibn.fm/Qivbd). A deficit, therefore, reflects an inability to recognize familiar faces. Face or social recognition deficits are frequently reported in patients with AD and are attributed to memory impairment. Therefore, the findings from the 2014 study suggest that CBD prevents the development of this symptom. For Lexaria, however, such findings are only part of the key motivators to commence the animal study on dementia. Others include the fact that the company has previously conducted efficacy studies evaluating DehydraTECH-CBD in humans with hypertension, revealing that the compound does not have any severe side effects and lowers human blood pressure (“HBP”). Coincidentally, a causal relationship exists between HBP and a type of dementia called vascular dementia – people with HBP are more likely to develop vascular dementia because of HBP-induced reduced blood flow to the brain. Moreover, the company has demonstrated in animal studies that DehydraTECH-CBD crosses the blood-brain barrier (“BBB”) much more effectively than originally thought possible. Ordinarily, the BBB blocks entry into the brain of most drugs in circulation, making it difficult to develop treatments for brain diseases. By crossing this barrier, however, DehydraTECH-CBD lends itself to science as a potential treatment for brain diseases such as dementia. Against this backdrop of favorable conditions, Lexaria is excited to investigate whether DehydraTECH-CBD might have some therapeutic benefits on dementia. The move and results, if positive, will usher the company into a burgeoning dementia drug market that analysts at Acumen Research and Consulting project will grow from $15.5 billion in 2021 to an estimated $32.3 billion by 2030, representing an 8.7% CAGR from 2022 to 2030 (https://ibn.fm/2epjA). For more information, visit the company’s website at www.LexariaBioscience.com. NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX

Lift Vancouver 2023 is to be held at the Vancouver Convention Center from January 12-14, 2023. Lift is a leading event-organizing company engaged in organizing high-quality cannabis events in North America, each of which is curated and designed for multiple audiences within the cannabis industry and community. The event is a grand forum for both established and new businesses, offering them the opportunity to gain visibility in the wider cannabis spectrum and the chance at discovery by investors, partners and media.

Attended by cannabis industry stalwarts and fresh voices alike, this coveted event showcases the presence of cannabis businesses, growers, entrepreneurs, regulators and innovators, as well as cannabis enthusiasts. But there’s more to Lift than just business. Enjoy unique activations (think games, photo opps and more), plus music, giveaways and an after party where attendees can connect with the industry in an informal setting.

Lift Vancouver 2023 will begin with the Lift Cannabis Business Conference on January 12, 2023, a premier conference that features top industry leaders and experts who will share cutting-edge knowledge-based sessions. Attendees can gain a wealth of information and learn new strategies about the latest offerings in the world of the cannabis trade through these valuable speaker sessions. From health to recreation, all facets of the cannabis trade and industry will be explored at the conference.

The trade show then commences from January 13-14, 2023, where hundreds of exhibiting companies will showcase their offerings. It’s the ideal setting for the cannabis community to learn about the latest products being launched in the market, as well as compare technology and preview new innovations.  Also, two new neighborhoods, a Brand Discovery Pavilion and Cannabis Retailer Zone, will bring novel experiences to budtenders and consumers.

Speaking of budtenders, another highlight of the Lift event is the Lift Budtender Program, celebrating these under-recognized cannabis industry members. The event will offer budtenders perks including free entry to the show (with verified certificate number) and a dedicated lounge area with giveaways and refreshments.

Lift Vancouver 2023 tickets are on sale now. To learn more and purchase tickets, visit https://liftexpo.ca/lift-co-expo-vancouver-2023/.

Mining leaders and professionals, policymakers, regulators, investors, and educators, are invited to the Resourcing Tomorrow – Mines and Money London conference, being held November 29 – December 1, 2022, at the Business Design Centre, London. The topics to be covered by experts are dedicated to global sustainability goals, including energy transition, ESG, decarbonization, and the circular economy. Mines and Money London is Europe’s leading conference that offers valuable insights into mining, energy and sustainability. witness 2000 attendees with 150+ businesses pitching their goals and ideas in front of 500+ potential investors. Be a part of the 120 talks, panel discussions and keynote presentations. Connect with industry leaders for meaningful interactions and robust networking across the three days. Some giant companies involved in the conference include Rio Tinto, Alcoa, Barrick, Ma’aden, and Anglo-American. As we enter a transitional age where world leaders need to rethink, assess and redesign political, social and economic strategies, be a part of these important business decisions and strategies being laid out at Resourcing Tomorrow. Every year, global leaders from the mining and energy spectrum participate in these conferences to learn and understand the latest offerings, and trends and look out for business opportunities. Some important topics at the conference:

• How the mining industry can contribute to transitioning energy to a green economy
• Discovering and embracing new methods into business such as digitalization, AI, mineral processing, tailings and water management
• As ESG moves from strategy to implementation discussion on topics like ESG metrics, SDPs, and better community engagement becomes vital
• Exploration of geopolitical perspective by addressing supply chain disruption, the impact of the war in Ukraine and resource nationalism issues

Mines and Money is dedicated to providing this international forum where organizers curate the events so that industry leaders and all attendees have access to quality content. They interact, discuss, collaborate, and develop long-term business ties. These participants and leaders include C-suite, Vice Presidents, Heads and Managers of mining companies from all levels. Newbies and budding mining and energy industries can leverage investor opportunities to connect with leading investors, financiers, and industry professionals from across the globe. World-renowned analysts and mining industries will grace the occasion and offer their expert opinion and suggestions on important topics. To learn more, please visit https://ibn.fm/JQkra.

• REZYFi is a Miami, Florida-headquartered growth mortgage origination and specialized financing company that primarily targets licensed and permitted cannabis companies and owners of real estate who lease to cannabis companies
• Traditional banks are governed by federal law, which criminalizes marijuana; as a result, they are hesitant to offer financial services to cannabis businesses
• The President recently set a process in motion that could culminate in the rescheduling of marijuana, although given that this review will not actually decriminalize the substance, the status quo, which disadvantages cannabis companies, will remain
• REZYFi believes cannabis-related companies will continue to experience difficulties accessing financing from traditional banks, presenting a major opportunity

Last month, the President called for marijuana rescheduling by directing the Secretary of Health and Human Services and the Attorney General to “initiate the administrative process to review expeditiously how marijuana is scheduled under federal law” (https://ibn.fm/BV6RE). Currently, marijuana is classified in Schedule 1 of the Controlled Substances Act of 1970, a category reserved for drugs that, according to the US Drug Enforcement Administration (“DEA”), have a high potential for abuse with no accepted medical use (https://ibn.fm/WyVsr). In rationalizing his October 6 announcement, the President noted that “this is the same schedule as for heroin and LSD, and even higher than the classification of fentanyl and methamphetamine – the drugs that are driving our overdose epidemic.” As consequential as the announcement might be, a recent article in MJBizDaily notes that this order has unleashed “a very long, very complex, and very unpredictable force on the world that might yet wreak unintended havoc” (https://ibn.fm/jyJth). This is because of the many unknowns associated with the move. For instance, it could enable struggling American marijuana firms to enjoy tax relief under Section 280E of the federal tax code. At the same time, however, large pharmaceutical companies could be incentivized to enter the cannabis industry, usurping business from existing but smaller players. Moreover, at a legislative level, an act of Congress could cancel out the recommendations that emerge from the review process. And even if the rescheduling were successful, there are cons associated with each new schedule under which marijuana could be classified. For instance, the MJBizDaily article notes, rescheduling marijuana as a Schedule 2 drug will mean that cannabis companies will have to endure the arduous and expensive FDA approval process before their products can enjoy legal relief. Moreover, a new Schedule 3 or 4 status will still require FDA approval even though the cannabis industry is not designed to comply with it. Finally, reclassification to Schedule 5 will only permit marijuana’s use for medical purposes and not responsible recreational use. Nevertheless, regardless of whichever schedule marijuana falls under post-rescheduling, the review, as is, will not decriminalize the substance. And as a result, the status quo, which sees cannabis-related companies struggle to obtain financing from traditional banks, may remain. (Traditional banks abide by federal law, which currently criminalizes marijuana use.) This presents a gap that REZYFi and its wholly owned subsidiaries, REZYFi Lending and ResMac, have sought to fill. In fact, REZYFi believes cannabis-related firms will continue to experience difficulties obtaining financing from traditional sources – the rescheduling efforts notwithstanding – creating opportunity for the company. REZYFi is a growth mortgage origination and specialized financing company headquartered in Miami, Florida. The company primarily offers a variety of real-estate-related first and additional mortgage-based financing and project-specific financings to licensed and permitted cannabis companies and owners of real estate who lease to cannabis companies. Through REZYFi Lending, the company provides specialty lending, cannabis commercial lending, and cannabis working capital letter of credit (“LOC”). On the other hand, it offers correspondent, retail, and wholesale mortgages through ResMac. REZYFi believes the demand for innovative financing offerings by players in the cannabis market will continue to grow as more geographic markets legalize recreational and medical cannabis usage, a belief that has fueled its expansion within the United States. Currently, REZYFi is licensed in 36 states but is looking to expand into additional jurisdictions. For more information, visit the company’s website at www.REZYFi.com. NOTE TO INVESTORS: The latest news and updates relating to REZYFi are available in the company’s newsroom at https://ibn.fm/REZY

• SideChannel recently released Enclave, its first software product
• The company acquired SideChannel in July 2022 and changed its name post-acquisition
• An industry benchmark study puts average CISO compensation at $463,000 annually, making SideChannel’s vCISO model attractive to its SMB target market
• According to IBM, the average cost to organizations of a cybersecurity breach is $4.2 million
• Cybersecurity Ventures reports a lack of trained professionals will leave 3.5 million cybersecurity positions unfilled by 2025, increasing demand for virtual security services

SideChannel (OTCQB: SDCH) simplifies cybersecurity for mid-market companies by matching them with highly experienced information security officers at a cost lower than building an in-house information security team or hiring a full-time CISO. SideChannel’s team of virtual Chief Information Security Officers (“vCISOs”) possesses a combined 400-plus years of experience in cybersecurity. They’ve honed their skills and abilities in places like Anthem, Dick’s Sporting Goods, Best Buy, TD Bank and the Pentagon. SideChannel lends this talent to clients, creating value in the form of a bespoke cybersecurity program perfectly sized for the growing enterprise. SideChannel is committed to creating top-tier cybersecurity programs for SMBs to help them protect their data and assets. To date, SideChannel has created more than 50 multi-layered cybersecurity programs for its clients. Reports show that cyberattacks on SMBs have increased in recent years, as organizations’ network attack surfaces have grown exponentially with remote and in-office workers increasingly relying on cloud environments, mobile devices, software applications and third-party suppliers to conduct business. SideChannel continues expanding its service offerings, workforce and customer base, attracting over 20 virtual CISOs to serve across industries including fintech, biotech, healthcare, manufacturing, legal, defense and technology services. The company is based in Worcester, Massachusetts. Market Opportunity An analysis from ReportLinker states that the global cybersecurity market is expected to grow from an estimated value of $173.5 billion in 2022 to $266.2 billion by 2027, recording a CAGR of 8.9% for the period. The increased number of data breaches worldwide, the ability of malicious actors to operate from anywhere in the world, the links between cyberspace and physical systems, and the difficulty of reducing vulnerabilities and consequences in complex cyber networks are some factors driving cyber security market growth, according to the report. A lack of cybersecurity professionals and the budget constraints among SMBs and start-ups in developing economies are expected to hinder market growth. Cybercriminals are using automated techniques to attack SMBs’ networks to take advantage of their weak security infrastructures. To save money, time and resources, SMBs are seeking cybersecurity solutions. Enclave Enclave expands upon SideChannel’s cybersecurity service offerings by solving a pervasive network security problem with a simple tool. A comprehensive cloud and network security solution, Enclave enables IT teams to contain breaches faster, reduce network outages, minimize latency and strengthen overall security defense. Enclave creates the foundation for a Zero Trust network security model IT can build upon. With Enclave, IT can easily segment their company’s network, organize personnel and computing devices at the employee workload level, and implement security controls across all network segments. Enclave was designed and purpose built to serve the growing security needs of SMBs, a traditionally underserved market that is more prone to cyberattacks but has limited protection due to smaller budgets, inadequate IT security staffing and a lack of cybersecurity awareness among top executives. Enclave is an affordable and effective network security solution that shrinks the attack surface area exposed to a cyber intruder and significantly reduces the amount of effort required to operate securely. Management Team Brian Haugli is CEO of SideChannel. He has led programs for the U.S. Department of Defense, the Pentagon, and Fortune 500 companies. He is an expert on National Institute of Standards and Technology guidance, threat intelligence implementations and strategic organizational initiatives. He is a professor at Boston College, Woods College of Advancing Studies Master’s Program in Cybersecurity. He is also a contributing author for the Wiley book ‘Cybersecurity Risk Management’. Ryan Polk is CFO at SideChannel. He has been the principal of Perissos Partners, an executive consulting firm, since June 2017. He also served in executive roles in the portfolio companies owned by Lacy Diversified, with combined revenue approaching $2 billion. He served as the Vice President for Corporate Financial Planning and Analysis for Brightpoint, a publicly traded, Fortune 500 mobile device logistics company. He earned a bachelor’s degree in accounting and industrial management from Purdue University. Nicholas Hnatiw is Chief Technology Officer at SideChannel. Prior to joining the company, he served as the technical director for network operations supporting U.S. Cyber Command, U.S. Intelligence Agencies and other Department of Defense research organizations. He was also the CEO of Loki Labs, a cyber security firm. He earned a bachelor’s degree in computer engineering and computer science at the University of Massachusetts, Amherst. Bill Roberts is SideChannel’s CISO. He most recently served as the vice president, IS & CISO for Hologic Inc., a global medical device company, where he established cyber security and IT compliance programs. Prior to Hologic, he was vice president of information security for Cytyc Corporation, which was acquired by Hologic in 2007. At Cytyc, he managed global IT as the company grew from 140 employees to 1,500 and from $40 million in revenue to over $750 million. For more information, visit the company’s website at www.SideChannel.com. NOTE TO INVESTORS: The latest news and updates relating to SDCH are available in the company’s newsroom at https://ibn.fm/SDCH

• With the recently passed Inflation Reduction Act, Correlate looks to achieve significant net gains
• The company just posted a significant revenue bump from $236,690 in Q2 2022 to $2,313,577 in Q3 2022, plus shows project opportunities of up to $194 million
• Todd Michaels, Correlate’s CEO, has also noted the company’s finalized M&A plans through Q2 2023, integral to scaling up the size and overall value of its projects and further growing revenue
• In September, the company entered into a non-binding letter of intent to acquire Vermont-based Aegis Renewable Energy Inc., which, once finalized, will present Correlate with new strategic abilities to explore the bludgeoning Northeast renewable energy market

Correlate Infrastructure Partners (OTCQB: CIPI), a tech-enabled development, finance, and fulfillment platform for distributed energy solutions across North America, just released its financial report for the third quarter of the 2022 financial year (“Q3 2022”). Of obvious note was the significant bump in revenue from $236,690 in Q2 2022 to $2,312,577. While speaking during the announcement, Todd Michaels, Correlate’s CEO, lauded the company’s performance and expressed his optimism for the company’s future, particularly with the enactment of the Inflation Reduction Act (https://ibn.fm/wVfqP). Mr. Michaels acknowledged the Act, citing its benefits to clients and investors in the renewable energy space, reporting that the move will be a significant net gain for the company and integral in opening it up to new markets in 2023. “The Inflation Reduction Act enacted in late August provided new tax incentives that reduce costs for clients and/or elevate returns to investors; this led to larger contract sizes with redesigns to domestic content,” noted Mr. Michaels. “While this meant delaying some project starts, it will be a big net gain, and will open new markets for us in 2023,” he added. The Inflation Reduction Act was designed to offer renewable technologies tax credits. While it promises immediate results and benefits, the most significant impact is projected to be felt toward the end of the decade once supply-chain issues are fixed. For example, through this Act, it is estimated that solar power plants built between 2022 and 2030 will generate over 364 gigawatts of electricity, which is more than three times the capacity of all US solar plants in operation in 2021 (https://ibn.fm/Gupzo). Currently, Correlate has project opportunities valued at up to $194 million, with projects in development that have been awarded agreements and contracts that have been executed and are under installation. With the implemented Act, it looks to significantly scale up its projects’ size and overall value, ultimately growing its revenue and creating even more value for its shareholders. This will also be achieved by Correlate’s ambitious M&A plan, which Mr. Michaels notes the company has already finalized. “With this in mind [anticipated project delays], we have finalized our M&A plans through Q2 2023 and seek to close our first acquisition by year-end,” noted Mr. Michaels. In September, Correlate entered into a non-binding letter of intent to acquire Vermont-based Aegis Renewable Energy Inc., a leading commercial, industrial, and community solar company focused on solar project development and engineering, procurement, and construction (“EPC”). Through this acquisition, Correlate hopes to capitalize on new strategic abilities to explore the bludgeoning Northeast renewable energy market where some of the states in the region, such as Vermont, have set goals to meet 90% of their energy needs with renewable sources by 2050 (https://ibn.fm/f5DuI). Correlate remains optimistic about its performance going forward and looks to capitalize on new and existing opportunities to achieve its short-term and long-term goals. Mr. Michaels is confident that the recently-implemented Inflation Reduction Act will play an integral role in the company’s growth, expansion of its opportunity pipeline, and value creation for its shareholders. For company information, visit the company’s website at www.CorrelateInfra.com, including the following:

• Breaking Down Barriers To Your ESG Goals While Generating Additional Net Operating Income www.CorrelateInfra.com/our-process
• Platform Generates New Rent And Operating Income, Allowing You To Meet Your ESG Goals www.CorrelateInfra.com/program

NOTE TO INVESTORS: The latest news and updates relating to CIPI are available in the company’s newsroom at https://ibn.fm/CIPI

• Ammonia is a highly efficient carrier of both hydrogen and nitrogen, with nitrogen being a critical component to fertilizers and world food production, but traditional ammonia production results in large greenhouse gas emissions
• FuelPositive’s carbon-free “green ammonia” production technology represents an environmentally superior way of producing ammonia
• The company’s confidence in its product has seen it go the extra mile to develop on-farm containerized, green ammonia production systems, that can be leveraged on a smaller scale to create green ammonia for agricultural fertilizers on-site

FuelPositive (TSX.V: NHHH) (OTCQB: NHHHF), a company focused on licensing, partnership, and acquisition opportunities related to energy-efficient, climate-safe, and sustainable solutions and sustainability, recognizes the rapidly growing demand for green technologies. The need is formalized in the UN’s 2050 Net Zero Goal for the drastic reduction of greenhouse gas emissions (https://ibn.fm/JXpj9). While there is a warranted push towards solar and wind energy, the company is bringing something new and viable to the discussion: green ammonia. FuelPositive’s green ammonia offers something different, a commercially viable and sustainable green solution for use across various industries and applications such as agriculture, transportation, and energy generation. Ammonia is a highly efficient carrier of both hydrogen and nitrogen. While hydrogen is critical to prospects for a hydrogen economy, nitrogen is a critical component to fertilizers and world food production. However, traditional ammonia production results in large greenhouse gas emissions. FuelPositive’s carbon-free green ammonia production technology offers an innovative alternative solution to the concerns associated with traditional ammonia generation, minimizing greenhouse gas emissions. As a result, it offers technology to address storage problems associated with hydrogen production and use, and technology to allow the production of ammonia for agricultural fertilizers with minimum greenhouse gas emissions. In the field of agriculture, FuelPositive’s confidence in its product has seen it go the extra mile to develop on-farm, containerized, green ammonia production systems that can be leveraged on a smaller scale to create on-site green ammonia. This is a huge step for more environmentally friendly agriculture, since 80% or more of all ammonia produced is used for fertilizing agricultural crops (https://ibn.fm/Yh4xC). For more information, visit the company’s website at www.FuelPositive.com. NOTE TO INVESTORS: The latest news and updates relating to NHHHF are available in the company’s newsroom at https://ibn.fm/NHHHF

• BiondVax summarizes collaboration with the prestigious Max Planck Institute for Multidisciplinary Sciences and the University Medical Center Göttingen to discover and develop nanosized antibody (NanoAb) therapies that address underserved and growing markets, including COVID-19, psoriasis, asthma, psoriatic arthritis and wet macular degeneration.
• The global COVID-19 therapy market was valued at $16.8 billion in 2021 and is expected to grow at a CAGR of 20% during the forecast period, resulting in a value of $35.42 billion by 2025
• The psoriasis market is experiencing a higher-than-expected demand across all regions due to the increasing geriatric population and the growing prevalence of plaque psoriasis and psoriatic arthritis resulting in an anticipated value of $47.24 billion by 2029

Joshua E. Phillipson, BiondVax Pharmaceuticals (NASDAQ: BVXV) Director of Communications and Investor Relations, recently presented the company’s corporate presentation to investors attending the LD Micro Main Event hosted by SRAX, Inc. at the Luxe in Los Angeles and online via Sequire Virtual Events platform October 25-27, 2022. The LD Micro Main Event, known as the “Woodstock” of the micro-cap world, has been showcasing the next big names in the space for the last 15 years. Phillipson was provided with 25 minutes on the main stage to offer investors an in-depth look at the company. The video is available at https://me22.sequireevents.com/recording?session_id=c2bc57cd-a925-43b2-8441-9f927a64b4f7 (free registration required).

BiondVax is a biotechnology company focused on developing, manufacturing, and commercializing innovative immunotherapeutic products primarily for the treatment of infectious diseases and autoimmune diseases. BiondVax is developing a pipeline of innovative nanosized antibody (NanoAb) therapies addressing diseases underserved by current treatments and with large and growing markets, such as COVID-19, psoriasis, asthma, psoriatic arthritis and wet macular degeneration. The company currently collaborates with the prestigious Max Planck Institute for Multidisciplinary Sciences (“MPG”) and the University Medical Center Göttingen (“UMG”), both in Germany.

Phillipson shared the company’s significant potential for value creation with the investors in attendance and online during the LD Micro event. BiondVax is targeting a massive, validated, addressable market with a pipeline of de-risked NanoAbs with a lead candidate to treat COVID-19 as a self-administered inhaled therapy that has a strong competitive edge. With seasoned scientific leadership and state-of-the-art laboratories and GMP biologics manufacturing facility, the company is well-positioned to bring innovative therapies to market with unique large pharma competencies. Key catalysts for BiondVax are expected in 2022 and 2023.

The company is tapping into the markets of multiple indications to create avenues where there is an unmet need for pharmaceutical therapies. The global COVID-19 therapy market was valued at $16.8 billion in 2021 and is expected to grow at a CAGR of 20% during the forecast period, resulting in a value of $35.42 billion by 2025 (https://ibn.fm/qgzIB). Additionally, BiondVax is planning to target the psoriasis treatment market, which was valued at $24.33 billion globally in 2021. This market is projected to grow to $47.24 billion by 2029 at a CAGR of 8.7%. The psoriasis market is experiencing a higher-than-expected demand across all regions due to the increasing geriatric population and the growing prevalence of plaque and psoriatic arthritis (https://ibn.fm/rOSNg).

The company brings significant clinical and commercial advantages to the collaboration with Max Planck including:

• Infectious disease and recombinant protein drug development experience from lab to Phase 3 clinical trial
• Manufacturing quality and international regulatory experience
• A GMP biologics manufacturing facility well suited to NanoAb production
• Top-tier big pharma and biotech leadership experience
• World-class science and access to leading scientists
• NanoAb platform for the development of promising potent therapeutics
• Exclusive rights to exclusive worldwide licenses covering patented NanoAbs and their manufacturing

BiondVax’s de-risked NanoAbs feature a favorable path to market compared to the risks associated with traditional drug treatments. Compared to monoclonal antibodies (“mAbs”) and oral therapies, the company provides multiple crucial advantages that offer convenience and flexibility backed by clinical benefits.

For more information, visit the company’s website at www.BiondVax.com.

NOTE TO INVESTORS: The latest news and updates relating to BVXV are available in the company’s newsroom at https://ibn.fm/BVXV